A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances

Author:

Zhao Lijun1,Li Shuhong1,Wei Xiaoyi1,Qi Xuexiu1,Guo Qiaoru1,Shi Licai1,Zhang Ji-shuai2,Li Jun3,Liu Ze-lin4,Guo Zhi4,Zhang Hongyu5,Feng Jia5,Shi Yuanyuan6,Zhang Suping7,Cao Yu J18ORCID

Affiliation:

1. State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School , Shenzhen 518055, China

2. The Shenzhen Pregene Biopharma Company, Ltd. , Shenzhen 518118, China

3. Fundamenta Therapeutics Co., Ltd , Suzhou 215200, China

4. Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital , Shenzhen 518052, China

5. Department of Hematology, Peking University Shenzhen Hospital , Shenzhen 518036, China

6. Shenzhen Cell Valley Biomedical Co., LTD , Shenzhen 518118, China

7. Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center , Shenzhen University Medical School, Shenzhen 518055, China

8. Institute of Chemical Biology, Shenzhen Bay Laboratory , Shenzhen 518132, China

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3